Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-04-02 16:53:14 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
VC Samara, N Thottempudi, O Franke…
American Journal of …, 2026
journals.lww.com
Background: Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder with significant unmet needs despite conventional therapies. Novel FcRn and complement inhibitors have transformed the treatment paradigm for generalized MG. Methods: This commentary reviews the clinical efficacy, safety, and practical implications of FDA-approved FcRn inhibitors (efgartigimod, rozanolixizumab, nipocalimab) and complements inhibitors (eculizumab, ravulizumab, zilucoplan), drawing on clinical trial data and literature from 2013 …
